

**2018 - 1**

**Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis**

*Khalilieh Sauzanne<sup>1</sup>, Hussain Azher<sup>1</sup>, Montgomery Diana<sup>1</sup>, Levine Vanessa<sup>1</sup>, Shaw Peter Martin<sup>1</sup>, Bodrug Inga<sup>2</sup>, Mekokishvili Lally<sup>3</sup>, Bailey-Smith Candice<sup>1</sup>, Glasgow Xiaoli Shirley<sup>1</sup>, Cheng Amy<sup>1</sup>, Martinho Monika<sup>1</sup>, Iwamoto Marian<sup>1</sup>*

<sup>1</sup> Merck and Co., Inc., Kenilworth,

<sup>2</sup> F.C.E. ARENSIA Exploratory Medicine,

<sup>3</sup> ARENSIA Exploratory Medicine LLC

**British Journal of Clinical Pharmacology**

Vol. 84, / 2018 / ISSN 0306-5251

Disponibil online 5 December, 2018. Descarcări-0. Vizualizări-764

---



Copyright © 2011-2024 Instrumentul Bibliometric Național.

Institutul de Dezvoltare a Societății Informaționale.

Actualizat: 29.06.2024, accesat: 30.06.2024

Disponibil: <https://ibn.idsi.md>

